2021 CMSC Annual Meeting

Tag: PhD5

Poster-Quality of Life and Outcomes

Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis

Background: Multiple sclerosis (MS) clinical trials often include patient-reported outcomes (PROs) to quantify treatment effects not...

Read More

Poster-Relapse Therapy

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Background: Satralizumab reduced relapse risk vs placebo in neuromyelitis optica spectrum disorder (NMOSD) patients and had a favourable...

Read More

Poster-Quality of Life and Outcomes

Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis

Background: Multiple Sclerosis (MS) is well known to reduce work productivity and adversely affect usual activities. Although previous...

Read More

Poster-Quality of Life and Outcomes

Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment Using Longitudinal Data from the Phase III Optimum Study

Background: Fatigue is a common symptom experienced by patients with Multiple Sclerosis (MS); and, the impact of fatigue on work...

Read More

Poster-Psychosocial Factors

Association of Lifestyle Physical Activity with Physical and Cognitive Fatigue in Individuals with Relapsing Remitting Multiple Sclerosis

Background: Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS). Participation in physical activity is...

Read More

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases

Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine if the...

Read More

Poster-Non-imaging Biomarkers

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More

Poster-Non-imaging Biomarkers

The Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...

Read More

Poster-Imaging

Relationship of Functional Outcomes and Routinely Performed MRI Studies in Persons with Multiple Sclerosis: An Insight into the Frontal Lobe Structural Alterations

Background: Functional outcomes in multiple sclerosis (MS) have been thoroughly investigated over the last few decades. The Frontal lobe...

Read More

Poster-Multidisciplinary Care

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Background: Historically, multiple sclerosis (MS) has been underdiagnosed among African Americans with MS (AAwMS). Recent evidence suggests...

Read More